Preprint Article Version 1 This version is not peer-reviewed

Daily Cisplatin and Weekly Docetaxel Versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial

Version 1 : Received: 5 May 2018 / Approved: 7 May 2018 / Online: 7 May 2018 (08:48:20 CEST)

How to cite: Hayashi, Y.; Minamiyama, S.; Ohya, T.; Iida, M.; Iwai, T.; Koizumi, T.; Oguri, S.; Hirota, M.; Kioi, M.; Hata, M.; Taguri, M.; Mitsudo, K. Daily Cisplatin and Weekly Docetaxel Versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial. Preprints 2018, 2018050110 (doi: 10.20944/preprints201805.0110.v1). Hayashi, Y.; Minamiyama, S.; Ohya, T.; Iida, M.; Iwai, T.; Koizumi, T.; Oguri, S.; Hirota, M.; Kioi, M.; Hata, M.; Taguri, M.; Mitsudo, K. Daily Cisplatin and Weekly Docetaxel Versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial. Preprints 2018, 2018050110 (doi: 10.20944/preprints201805.0110.v1).

Abstract

Purpose: The aim of present study was to compare the treatment results of daily cisplatin (CDDP), weekly docetaxel (DOC) intra-arterial infusion chemotherapy combined with radiotherapy (DIACRT) regimen and weekly CDDP intra-arterial infusion chemotherapy combined with radiotherapy (WIACRT) for patients with tongue cancer. Materials and Methods: Between January 2007 and December 2016, a total of 11 patients treated with WIACRT and 45 patients treated with DIACRT were enrolled in present study. In DIACRT group, 25 patients had T2, 20 patients had T3. A total of 9 patients had T2 and 2 had T3 in WIACRT (p = NS). In DIACRT, the treatment schedule consisted of intra-arterial chemotherapy (DOC, total 60 mg/m2; CDDP, total 150 mg/m2) and daily concurrent radiotherapy (RT) (total, 60 Gy). In WIACRT, the treatment schedule consisted of intra-arterial chemotherapy (CDDP, total 360 mg/m2) and daily concurrent RT (total, 60 Gy). Results: The median follow-up periods for DIACRT and WIACRT were 61 and 66 months respectively. The 5-year local control (LC) and overall survival (OS) rate were 94.5% and 89.6% for DIACRT group, 60.6% and 63.6% for WIACRT group respectively. The LC rate and OS of DIACRT group were significantly higher than that of WIACRT group. As regards toxicities, no treatment-related deaths were observed during the follow-up periods both in two groups. Conclusions: DIACRT was found to be feasible and effective for patients with tongue cancer and could become a new treatment modality.

Subject Areas

oral cancer; radiotherapy; intra-arterial chemotherapy; head and neck cancer

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.